Reported 1 day ago
Viking Therapeutics experienced a decline of more than 10% in its stock price this week due to a new licensing deal announced by Merck for a promising GLP-1 obesity drug developed by Hansoh Pharma. As Merck secures rights to the drug HS-10535 with significant financial commitments, potential competition in the obesity treatment market poses a challenge for Viking, which is concurrently developing its own oral obesity treatment, VK2735, that has shown promise in trials.
Source: YAHOO